Repligen Corporation
RGENNASDAQHealthcare● Active
$122.31
$-4.24(-3.35%)
Market Cap$6.9B
P/E Ratio—
52W High$175.77
52W Low$100.99
Repligen Corporation (RGEN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RGEN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
$0.48
Est. $0.38 · +26.3%
Revenue
$0.19B
Est. $0.19B · +1.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
RGEN reports quarterly as a NASDAQ-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.46 | — | — | — | $0.20B | — |
| ▲ Q2 FY2026 | May 5, 2026 | $0.38 | $0.48 | +26.3% | $0.19B | $0.19B | +1.1% |
| ▲ Q1 FY2026 | Feb 24, 2026 | $0.44 | $0.49 | +11.4% | $0.20B | $0.19B | +2.6% |
| ▲ Q4 FY2025 | Oct 28, 2025 | $0.42 | $0.46 | +9.5% | $0.19B | $0.19B | -1.8% |
| ▼ Q3 FY2025 | Jul 29, 2025 | $0.40 | $0.37 | -7.5% | $0.18B | $0.18B | +0.3% |
| ▲ Q2 FY2025 | Apr 29, 2025 | $0.35 | $0.39 | +11.4% | $0.17B | $0.17B | -2.5% |
| ▲ Q1 FY2025 | Feb 20, 2025 | $0.41 | $0.44 | +7.3% | $0.17B | $0.16B | +2.1% |
| ▲ Q4 FY2024 | Nov 12, 2024 | $0.34 | $0.43 | +28.2% | $0.15B | $0.15B | +1.2% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.46
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Beat
EPS Actual
$0.48
EPS Est.
$0.38
EPS Surpr.
+26.3%
Revenue
$0.19B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$0.49
EPS Est.
$0.44
EPS Surpr.
+11.4%
Revenue
$0.20B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
$0.46
EPS Est.
$0.42
EPS Surpr.
+9.5%
Revenue
$0.19B
Q3 FY2025
Jul 29, 2025Miss
EPS Actual
$0.37
EPS Est.
$0.40
EPS Surpr.
-7.5%
Revenue
$0.18B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
$0.39
EPS Est.
$0.35
EPS Surpr.
+11.4%
Revenue
$0.17B
Q1 FY2025
Feb 20, 2025Beat
EPS Actual
$0.44
EPS Est.
$0.41
EPS Surpr.
+7.3%
Revenue
$0.17B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
$0.43
EPS Est.
$0.34
EPS Surpr.
+28.2%
Revenue
$0.15B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.87 | $0.89 | $0.90 | 5 |
| Q3 FY2028 | $0.82 | $0.84 | $0.86 | 10 |
| Q2 FY2028 | $0.80 | $0.82 | $0.83 | 7 |
| Q1 FY2028 | $0.76 | $0.78 | $0.79 | 5 |
| Q4 FY2027 | $0.73 | $0.75 | $0.76 | 4 |
| Q3 FY2027 | $0.63 | $0.64 | $0.65 | 8 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.3B | $0.3B | $0.3B | 4 |
| Q3 FY2028 | $0.3B | $0.3B | $0.3B | 9 |
| Q2 FY2028 | $0.3B | $0.3B | $0.3B | 6 |
| Q1 FY2028 | $0.2B | $0.2B | $0.3B | 4 |
| Q4 FY2027 | $0.2B | $0.3B | $0.3B | 5 |
| Q3 FY2027 | $0.2B | $0.2B | $0.2B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 5, 2026 | +26.3% | $118.21 | $125.61 | +6.26% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +11.4% | $135.40 | $134.67 | -0.54% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +9.5% | $161.10 | $151.57 | -5.92% |
| ▼ Q3 FY2025 | Jul 29, 2025 | -7.5% | $119.65 | $125.30 | +4.72% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +11.4% | $143.63 | $139.43 | -2.92% |
| ▲ Q1 FY2025 | Feb 20, 2025 | +7.3% | $150.73 | $162.67 | +7.92% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +28.2% | $139.51 | $148.59 | +6.51% |
| ▲ Q3 FY2024 | Jul 30, 2024 | +0.0% | $138.00 | $160.59 | +16.37% |
Q2 FY2026+6.26%
Report Date
May 5, 2026
EPS Beat/Miss
+26.3%
Price Before
$118.21
Price After
$125.61
Q1 FY2026-0.54%
Report Date
Feb 24, 2026
EPS Beat/Miss
+11.4%
Price Before
$135.40
Price After
$134.67
Q4 FY2025-5.92%
Report Date
Oct 28, 2025
EPS Beat/Miss
+9.5%
Price Before
$161.10
Price After
$151.57
Q3 FY2025+4.72%
Report Date
Jul 29, 2025
EPS Beat/Miss
-7.5%
Price Before
$119.65
Price After
$125.30
Q2 FY2025-2.92%
Report Date
Apr 29, 2025
EPS Beat/Miss
+11.4%
Price Before
$143.63
Price After
$139.43
Q1 FY2025+7.92%
Report Date
Feb 20, 2025
EPS Beat/Miss
+7.3%
Price Before
$150.73
Price After
$162.67
Q4 FY2024+6.51%
Report Date
Nov 12, 2024
EPS Beat/Miss
+28.2%
Price Before
$139.51
Price After
$148.59
Q3 FY2024+16.37%
Report Date
Jul 30, 2024
EPS Beat/Miss
+0.0%
Price Before
$138.00
Price After
$160.59
Avg Beat Reaction+3.95%
Avg Miss Reaction+4.72%
Beat Rate7 / 8 quarters
Largest Move+16.37% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RGEN ends December
Repligen Corporation (RGEN) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $0.48 — beating the analyst consensus of $0.38 by +26.3%. RGEN has beaten EPS estimates for 3 consecutive quarters. The next RGEN earnings date is expected around September 1, 2026.
Each quarter, investors track RGEN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RGEN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RGEN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RGEN earnings · 5 questionsRepligen Corporation's next earnings report is expected around September 1, 2026. RGEN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RGEN historically reports after market close (AMC).
RGEN earnings datewhen is RGEN earningsRGEN next earnings datewhen does RGEN report earningsRGEN earnings calendar
▸ Source: FMP · Repligen Corporation SEC filings · US GAAP · Repligen Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026